Overview

Assessing the Pharmacokinetics of NKTR-118 in Subjects With Renal Impairment Compared to That in Subjects With Normal Renal Function

Status:
Completed

Trial end date:
2011-11-01

Target enrollment:

Participant gender:

Summary

This study will be assessing the pharmacokinetics of NKTR-118 in subjects with renal impairment compared to that in subjects with normal renal function.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Treatments:

Naloxegol